{"id":18602,"date":"2021-08-04T11:27:56","date_gmt":"2021-08-04T15:27:56","guid":{"rendered":"https:\/\/medicarereport.org\/?p=18602"},"modified":"2021-08-04T11:27:56","modified_gmt":"2021-08-04T15:27:56","slug":"alzheimers-patients-are-in-limbo-as-hospitals-insurers-grapple-with-whether-to-offer-aduhelm","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=18602","title":{"rendered":"Alzheimer\u2019s patients are in limbo as hospitals, insurers grapple with whether to offer Aduhelm"},"content":{"rendered":"<p>(By Andrew Joseph and Rachel Cohrs for ST<em>A<\/em>T)<\/p>\n<p>For all the explosive controversy over the approval of the first treatment for Alzheimer\u2019s disease in nearly 20 years, hardly any patients have actually gotten it yet.\u00a0 Continue reading the article <a href=\"https:\/\/www.statnews.com\/2021\/08\/04\/alzheimers-patients-in-limbo-as-hospitals-insurers-grapple-aduhelm\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Andrew Joseph and Rachel Cohrs for STAT) For all the explosive controversy over the approval of the first treatment<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,15],"tags":[],"class_list":["post-18602","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18602","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18602"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18602\/revisions"}],"predecessor-version":[{"id":18603,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/18602\/revisions\/18603"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18602"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18602"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18602"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}